Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 279 drug-target rows in SSL view, for TSG = SH2B3.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab SH2B3 RET 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) SH2B3 RET 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SH2B3 MST1R 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SH2B3 RET 3
crizotinib SH2B3 MST1R 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan SH2B3 TOP1MT 3
pembrolizumab, belzutifan, lenvatinib SH2B3 RET 3
regorafenib SH2B3 RET 6
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel SH2B3 RET 2
alvocidib, paclitaxel SH2B3 CDK9 2
apatinib, irinotecan SH2B3 TOP1MT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan SH2B3 TOP1MT 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine SH2B3 TOP1MT 2
cabozantinib SH2B3 RET 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib SH2B3 RET 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery SH2B3 TOP1MT 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib SH2B3 RET 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study SH2B3 HDAC3 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a SH2B3 RET 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide SH2B3 TOP1MT 2
irinotecan, capecitabine SH2B3 TOP1MT 2
irinotecan, docetaxel SH2B3 TOP1MT 2
lenvatinib, pembrolizumab SH2B3 RET 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate SH2B3 RET 2
lurbinectedin, irinotecan SH2B3 TOP1MT 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab SH2B3 TOP1MT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a SH2B3 RET 2
pembrolizumab, guadecitabine, mocetinostat SH2B3 HDAC3 2
pembrolizumab, lenvatinib SH2B3 RET 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu SH2B3 RET 2
pembrolizumab, paclitaxel, docetaxel, irinotecan SH2B3 TOP1MT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin SH2B3 RET 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery SH2B3 RET 2
regorafenib, laboratory biomarker analysis SH2B3 RET 2
sorafenib, administered orally, ct/mri SH2B3 RET 2
selpercatinib SH2B3 RET 6
sorafenib SH2B3 RET 6
vandetanib SH2B3 RET 6
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat SH2B3 HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat SH2B3 HDAC3 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin SH2B3 TOP1MT 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan SH2B3 TOP1MT 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf SH2B3 TOP1MT 1
acetazolamide, temozolomide SH2B3 CA14 1
afatinib, irinotecan SH2B3 TOP1MT 1
alvocidib, docetaxel SH2B3 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis SH2B3 CDK9 1
aminolevulinic acid SH2B3 ALAD 1
aminolevulinic acid, surgical resection SH2B3 ALAD 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel SH2B3 TOP1MT 1
atezolizumab, cabozantinib SH2B3 RET 1
atorvastatin, temozolomide, radiotherapy SH2B3 NR1I3 1
avastin, temozolomide, irinotecan SH2B3 TOP1MT 1
avastin, temozolomide, radiation therapy (xrt), irinotecan SH2B3 TOP1MT 1
avelumab, irinotecan, paclitaxel, best supportive care (bsc) SH2B3 TOP1MT 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab SH2B3 HDAC3 1
azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine SH2B3 TOP1MT 1
bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 SH2B3 TOP1MT 1
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil SH2B3 TOP1MT 1
berzosertib, computed tomography assisted biopsy, endoscopic biopsy, irinotecan, magnetic resonance imaging SH2B3 TOP1MT 1
bevacizumab [avastin], irinotecan, temozolomide SH2B3 TOP1MT 1
bevacizumab, irinotecan SH2B3 TOP1MT 1
bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging SH2B3 TOP1MT 1
bevacizumab, temozolomide, radiation therapy (xrt), topotecan SH2B3 TOP1MT 1
bevacizumab, temozolomide, vorinostat SH2B3 HDAC3 1
biopsy, biospecimen collection, computed tomography, endoscopic ultrasound, fluorouracil, irinotecan, leucovorin, lymph node biopsy, magnetic resonance imaging, oxaliplatin, pembrolizumab, photodynamic therapy, positron emission tomography, questionnaire administration, verteporfin SH2B3 TOP1MT 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging SH2B3 RET 1
biopsy, biospecimen collection, crizotinib, radiologic examination SH2B3 MST1R 1
biospecimen collection, computed tomography, core biopsy, fluorouracil, irinotecan, leucovorin, leucovorin calcium, oxaliplatin, quemliclustat, zimberelimab SH2B3 TOP1MT 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography SH2B3 RET 1
bl-b01d1, irinotecan, paclitaxel, docetaxel SH2B3 TOP1MT 1
bortezomib, irinotecan SH2B3 TOP1MT 1
cabozantinib, durvalumab, tremelimumab SH2B3 RET 1
cabozantinib, nivolumab SH2B3 RET 1
cabozantinib, pembrolizumab SH2B3 RET 1
camrelizumab, docetaxel, irinotecan SH2B3 TOP1MT 1
camrelizumab, irinotecan, paclitaxel, paclitaxel-albumin, docetaxel, anlotinib SH2B3 TOP1MT 1
capecitabine, oxaliplatin, irinotecan SH2B3 TOP1MT 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor SH2B3 HDAC3 1
carboxylesterase-expressing allogeneic neural stem cells, irinotecan, irinotecan hydrochloride, laboratory biomarker analysis, pharmacological study SH2B3 TOP1MT 1
cetuximab, bevacizumab, irinotecan SH2B3 TOP1MT 1
cetuximab, irinotecan, oxaliplatin, uft SH2B3 TOP1MT 1
cisplatin, fluorouracil, gemcitabine, irinotecan, leucovorin, nab-paclitaxel, oxaliplatin, radiation therapy SH2B3 TOP1MT 1
cisplatin, irinotecan, capecitabine SH2B3 TOP1MT 1
digoxin, 5fluorouracil, calcium leucovorin, irinotecan, oxaliplatin SH2B3 TOP1MT 1
durvalumab, oxaliplatin, irinotecan, calcium folinate (leucovorin), fluorouracil, pegylated g-csf SH2B3 TOP1MT 1
eras-007, encorafenib, cetuximab, palbociclib SH2B3 LIMK2 1
eras-007, encorafenib, cetuximab, palbociclib SH2B3 MAPK8 1
erdafitinib SH2B3 RET 1
etomidate, midazolam, meperidine SH2B3 GRIN2B 1
everolimus, sorafenib SH2B3 RET 1
fluorouracil, irinotecan, irinotecan hydrochloride, leucovorin, leucovorin calcium, nivolumab, oxaliplatin, therapeutic conventional surgery SH2B3 TOP1MT 1
fluorouracil, leucovorin calcium, oxaliplatin, irinotecan, nivolumab, magnetic resonance imaging, computed tomography, biospecimen collection, questionnaire administration SH2B3 TOP1MT 1
fluorouracil, oxaliplatin, irinotecan SH2B3 TOP1MT 1
gemcitabine, erlotinib, sorafenib SH2B3 RET 1
gemcitabine, nab-paclitaxel, irinotecan, intensity-modulated radiation therapy (imrt) SH2B3 TOP1MT 1
gemcitabine, oxaliplatin, imatinib SH2B3 RET 1
gemcitabine, placebo, sorafenib SH2B3 RET 1
gemcitabine, sorafenib, radiotherapy SH2B3 RET 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff SH2B3 RET 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff SH2B3 HDAC3 1
gemcitabine, taxotere, xeloda, cisplatin, irinotecan SH2B3 TOP1MT 1
h101, tislelizumab, lenvatinib SH2B3 RET 1
ifinatamab deruxtecan, docetaxel, paclitaxel, irinotecan SH2B3 TOP1MT 1
irinotecan, 5-fluorouracil, leucovorin SH2B3 TOP1MT 1
irinotecan, bevacizumab, fdopa-pet/mri imaging SH2B3 TOP1MT 1
irinotecan, ibi343, paclitaxel SH2B3 TOP1MT 1
irinotecan, leucovorin, 5-fluorouracil, docetaxel, cisplatin, leucovorin, 5-fluorouracil SH2B3 TOP1MT 1
irinotecan, radiation therapy SH2B3 TOP1MT 1
irinotecan, ramucirumab, blood for angiome profiling, blood for cfdna SH2B3 TOP1MT 1
kc1036, irinotecan, docetaxel, s-1 SH2B3 TOP1MT 1
ketoconazole SH2B3 NR1I3 1
ko-2806, cabozantinib, adagrasib SH2B3 RET 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat SH2B3 HDAC3 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil SH2B3 RET 1
lenvatinib, bevacizumab SH2B3 RET 1
liposomal irinotecan, 5-fu, lv, irinotecan SH2B3 TOP1MT 1
ljm716, byl719, paclitaxel, docetaxel, irinotecan SH2B3 TOP1MT 1
ly3962673, cetuximab, gemcitabine, nab-paclitaxel, oxaliplatin, leucovorin, irinotecan, 5-fluorouracil SH2B3 TOP1MT 1
mebendazole, vincristine, carboplatin, temozolomide, bevacizumab, irinotecan SH2B3 TOP1MT 1
nab-paclitaxel, gemcitabine, capecitabine, cisplatin, irinotecan, nab-paclitaxel, gemcitabine, capecitabine, cisplatin, irinotecan SH2B3 TOP1MT 1
nab-paclitaxel, gemcitabine, cisplatin, irinotecan, capecitabine, pembrolizumab, olaparib SH2B3 TOP1MT 1
nabiximols, temozolomide, nabiximols-matched placebo SH2B3 CYP3A7 1
napabucasin, nab-paclitaxel, gemcitabine, nivolumab, paclitaxel, irinotecan, leucovorin, 5fluorouracil, bevacizumab SH2B3 TOP1MT 1
nivolumab, cabozantinib SH2B3 RET 1
np137, oxaliplatin, irinotecan, calcium levofolinate, 5 fu SH2B3 TOP1MT 1
olaparib, temozolomide, irinotecan SH2B3 TOP1MT 1
oxaliplatin, docetaxel, leucovorin, irinotecan, 5-fluorouracil SH2B3 TOP1MT 1
oxaliplatin, irinotecan, 5-fu, gemcitabine, radiation therapy SH2B3 TOP1MT 1
oxaliplatin, irinotecan, capecitabine SH2B3 TOP1MT 1
oxaliplatin, irinotecan, folinic acid, 5-fluorouracil, gemcitabine, capecitabine SH2B3 TOP1MT 1
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine SH2B3 TOP1MT 1
oxaliplatin, irinotecan, leucovorin, fluorouracil, laboratory biomarker analysis, flow cytometry, immunohistochemistry staining method, pharmacological study, pf-04136309 SH2B3 TOP1MT 1
oxaliplatin, sorafenib SH2B3 RET 1
oxaliplatine, folinic acid, irinotecan, 5-fu SH2B3 TOP1MT 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) SH2B3 RET 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) SH2B3 TOP1MT 1
panitumumab, irinotecan SH2B3 TOP1MT 1
pd-1 inhibitors, irinotecan, capecitabine tablets SH2B3 TOP1MT 1
pegph20, oxaliplatin, leucovorin, irinotecan, 5-fluorouracil SH2B3 TOP1MT 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel SH2B3 RET 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel SH2B3 TOP1MT 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel SH2B3 RET 1
pembrolizumab, vorinostat, temozolomide, radiotherapy SH2B3 HDAC3 1
pep02, irinotecan, docetaxel SH2B3 TOP1MT 1
ponatinib SH2B3 RET 1
radiation therapy, temozolomide, sorafenib SH2B3 RET 1
regorafenib, lomustine SH2B3 RET 1
regorafenib, nivolumab, capeox, folfox regimen SH2B3 RET 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil SH2B3 RET 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil SH2B3 TOP1MT 1
regorafenib, temozolomide SH2B3 RET 1
reolysin®, chemotherapy, gemcitabine, irinotecan, leucovorin, 5-fluorouracil, pembrolizumab SH2B3 TOP1MT 1
rmc-6236, gemcitabine, nab-paclitaxel, irinotecan, liposomal irinotecan, 5-fluorouracil, leucovorin, oxaliplatin SH2B3 TOP1MT 1
sacituzumab tirumotecan, trifluridine-tipiracil, irinotecan, paclitaxel, docetaxel, rescue medication, supportive care measures SH2B3 TOP1MT 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome SH2B3 RET 1
shr-a1904, paclitaxel, docetaxel, irinotecan SH2B3 TOP1MT 1
si-b001, irinotecan SH2B3 TOP1MT 1
simmitinib plus irinotecan liposome, irinotecan liposome, irinotecan SH2B3 TOP1MT 1
sirolimus, vandetanib SH2B3 RET 1
sorafenib, erlotinb SH2B3 RET 1
sorafenib, rad001 SH2B3 RET 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide SH2B3 RET 1
tace, lenvatinib, combined with tislelizumab group SH2B3 RET 1
tace, tislelizumab, lenvatinib SH2B3 RET 1
tamoxifen, etoposide SH2B3 MAPK8 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 SH2B3 RET 1
tislelizumab, paclitaxel, docetaxel, irinotecan SH2B3 TOP1MT 1
topotecan SH2B3 TOP1MT 1
topotecan, gadolinium dtpa, cleveland multiport catheter SH2B3 TOP1MT 1
topotecan, pazopanib SH2B3 TOP1MT 1
trc 105, sorafenib SH2B3 RET 1
vandetanib, 5 fluorouracil (fu), carboplatin, paclitaxel, external beam radiation therapy (rt) SH2B3 RET 1
vemurafenib, sorafenib SH2B3 RET 1
vorinostat, bevacizumab SH2B3 HDAC3 1
vorinostat, bevacizumab, irinotecan SH2B3 TOP1MT 1
vorinostat, bevacizumab, irinotecan SH2B3 HDAC3 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis SH2B3 HDAC3 1
vorinostat, conventional surgery SH2B3 HDAC3 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study SH2B3 HDAC3 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration SH2B3 HDAC3 1
vorinostat, therapeutic conventional surgery, bortezomib SH2B3 HDAC3 1
sterile SH2B3 KCNJ11 6
acamprosate SH2B3 GRIN2B 6
acamprosate calcium SH2B3 GRIN2B 6
acetyldigitoxin SH2B3 ATP1A4 6
alectinib SH2B3 RET 6
alectinib hydrochloride SH2B3 RET 6
allopurinol sodium SH2B3 XDH 6
amantadine SH2B3 GRIN2B 6
amantadine hydrochloride SH2B3 GRIN2B 6
atracurium SH2B3 CHRNA1 6
atracurium besylate SH2B3 CHRNA1 6
belantamab mafodotin SH2B3 TUBA3E 6
belantamab mafodotin SH2B3 TUBB2A 6
belinostat SH2B3 HDAC3 6
bendazac SH2B3 XDH 6
carfilzomib SH2B3 PSMA2 6
carfilzomib SH2B3 PSMA4 6
cisatracurium SH2B3 CHRNA1 6
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.